BUZZ-Disc Medicine shares fall after launching $350 million stock offering
路透社2026/10/19 20:32October 19 - ** Disc Medicine shares IRON.O fell 1.5% in after-hours trading to $77.77, as the company is planning an equity financing
** The biopharmaceutical company (link) has launched a $350 million financing plan, including stock and pre-funded warrants
(link) ** IRON shares closed up 38.9% at $78.93 on Monday after its drug bitopertin met all primary and secondary endpoints in a late-stage clinical trial for erythropoietic protoporphyria (EPP), a blood disorder that makes patients extremely sensitive to sunlight
** The success of this late-stage clinical trial (link) paves the way for the company to resubmit its application for bitopertin to the U.S. Food and Drug Administration (FDA) for review—after the agency had rejected the drug's application earlier this year
** IRON will use the net proceeds from this offering to fund the development of existing or new product candidates, to support the potential commercialization of bitopertin for the treatment of EPP and X-linked protoporphyria (XLP), and for other uses
** Jefferies, Leerink, Morgan Stanley, and Cantor Fitzgerald are acting as joint bookrunners
** Based in Watertown, Massachusetts, IRON has approximately 38.4 million shares outstanding and a market capitalization of about $3 billion
** According to LSEG data, all 13 analysts covering the stock are bullish; the median target price is $117.50
(To facilitate non-native English speakers, Reuters has automated the translation of its reports into several other languages. As automated translation may contain errors or lack contextual accuracy, Reuters does not guarantee the accuracy of translated texts and provides them for reader convenience only. Reuters accepts no responsibility for any damages or losses arising from the use of automated translation features.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment
According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.
GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions
Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.
BUZZ-3M India shares fall to 19-month low due to quarterly profit decline
Anthropic (ANT.US) to launch IPO roadshow next week, valuation may shrink from 1.5 trillion dollars to 1 trillion dollars! The AI capital feast faces a test.
After the AI sell-off, major investors are questioning whether Anthropic can go public at a $1.5 trillion valuation, or if it will be reduced to around $1 trillion. Fundraising may also decrease from $100 billion to $80 billion.
Crypto prices
More
